drugset
Drugs / P-CD19CD20-ALLO1
last change Oct 2025 re-read 9 days ago

P-CD19CD20-ALLO1

Cell therapy

Developed for
high grade B-cell lymphoma · multiple sclerosis · primary mediastinal large B-cell lymphoma
Investigated by
Genentech, Inc. · Poseida Therapeutics, Inc. · Poseida Therapeutics, Inc., a member of the Roche Group · Roche-Genentech

Trials 2

today NCT07008378 · Ph 1 NCT06014762 · Ph 1
20252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07008378 Oct 2025 → Aug 2032 expected multiple sclerosis Genentech, Inc. Active not recruiting No outcome recorded
Phase 1 NCT06014762 Apr 2024 → Mar 2029 expected high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma Poseida Therapeutics, Inc. Active not recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2024-11-05 Hoffmann-La Roche Results Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 roche.com ↗
P-CD19CD20-ALLO1: Potent Fully Allogeneic CAR-T Therapy Targeting CD19 and CD20 with Superior Efficacy Over Single-Target Products
2024-11-05 Genentech, Inc. Results Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024 gene.com ↗
P-CD19CD20-ALLO1: Potent Fully Allogeneic CAR-T Therapy Targeting CD19 and CD20 with Superior Efficacy Over Single-Target Products

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as P-CD19CD20-ALLO1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07008378 ↗
1

NCT06014762 ↗
Modality Cell therapy “allogeneic T stem cell memory (Tscm) CAR-T cells” NCT06014762 ↗
Route Intravenous “Single weight-based IV administration” NCT06014762 ↗